With dust set­tled on ac­tivist at­tack, Lau­rence Coop­er leaves Zio­pharm to a new board

Lau­rence Coop­er has done his part.

In the five years since he left a tenured po­si­tion at Hous­ton’s MD An­der­son Can­cer Cen­ter to be­come CEO of Boston-based Zio­pharm, he’s steered the small-cap im­munother­a­py play­er through pa­tient deaths in tri­als, clin­i­cal holds, short at­tacks and, most re­cent­ly, an ac­tivist at­tack on the board.

So when the com­pa­ny has “fan­tas­tic news” like an IND clear­ance for a TCR T cell ther­a­py pro­gram, he’s ready to pass on the ba­ton.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER